• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alkermes plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    2/25/26 9:31:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    8-K
    0001520262FalseAlkermes plc.00015202622026-02-242026-02-24

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): February 24, 2026

    ALKERMES PUBLIC LIMITED COMPANY

    (Exact name of registrant as specified in its charter)

     

    Ireland

     

    001-35299

     

    98-1007018

    (State or other jurisdiction

     

    (Commission

     

    (IRS Employer

    of incorporation)

     

    File Number)

     

    Identification No.)

     

     

     

     

     

     

    Connaught House, 1 Burlington Road

    Dublin 4, Ireland D04 C5Y6

    (Address of principal executive offices)

     

    Registrant's telephone number, including area code: + 353-1-772-8000

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Ordinary shares, $0.01 par value

     

    ALKS

     

    Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

     

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On February 24, 2026, Richard F. Pops, Chairman and Chief Executive Officer of Alkermes plc (the “Company”), notified the Company’s board of directors (the “Board”) of his decision to retire from his position of Chief Executive Officer, effective July 31, 2026, following a distinguished 35 years of service in this role.

     

    To support the Company during this transition, Mr. Pops will serve as a Senior Advisor to the Company through December 31, 2026 (the “Senior Advisor Service Term”) and will remain on the Board, serving as non-executive Chairman.

     

    The Board thanks Mr. Pops for his visionary leadership, his dedicated service and invaluable contributions to the Company’s growth and success, and his continued commitment to the Company through his transition and beyond.

     

    On February 24, 2026, the Board appointed Blair C. Jackson, the Company’s current Executive Vice President, Chief Operating Officer, to serve as the Company’s Chief Executive Officer, effective August 1, 2026, following Mr. Pops’ retirement. Mr. Jackson, age 53, has served as the Company’s Executive Vice President, Chief Operating Officer since January 2021, leading the Company’s global operations, quality, information technology, business development and corporate planning functions. He also served as interim principal financial officer of the Company from February 2024 to September 2025. Prior to assuming his current position, Mr. Jackson served in various strategic, scientific and corporate roles of increasing responsibility within the Company, including most recently as Senior Vice President, Corporate Planning of Alkermes, Inc., a subsidiary of the Company, from July 2018 to January 2021. Mr. Jackson earned a Bachelor of Arts in Biochemistry from the University of Calgary, a Bachelor of Arts in Chemical Engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in Chemical Engineering practice from the Massachusetts Institute of Technology.

     

    Mr. Jackson has not entered into any material plan, contract, arrangement or amendment in connection with this appointment. There are no family relationships between Mr. Jackson and any director or executive officer of the Company or person nominated or chosen by the Company to become a director or executive officer of the Company, and Mr. Jackson does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are also no arrangements or understandings between Mr. Jackson and any other person pursuant to which Mr. Jackson was selected as an officer of the Company.

     

    In connection with Mr. Pops’ retirement, on February 24, 2026, Mr. Pops entered into a letter agreement with the Company (the “Letter Agreement”) to memorialize the terms of his continued service as a Senior Advisor to the Company and non-executive Chairman of the Board. Pursuant to the Letter Agreement, Mr. Pops will be eligible to receive (i) a monthly cash retainer of $75,000 while serving as a Senior Advisor, (ii) a fiscal year 2026 annual cash bonus, expected to be paid in the first quarter of 2027, at the target level, pro-rated to reflect his service as Chief Executive Officer during fiscal year 2026, (iii) in lieu of a 2026 annual equity award, a time-based restricted stock unit award for fiscal year 2026, with a grant value of $2,687,500.00, which is consistent with Mr. Pops’ fiscal year 2025 annual equity incentive award, pro-rated to twelve-forty eighths (12/48) of such grant value to reflect Mr. Pops’ service during fiscal year 2026 through the Senior Advisor Service Term and scheduled to vest on December 31, 2026, and (iv) for his service as non-executive Chairman, an annual retainer of $40,000, pro-rated to reflect his term of service as non-executive Chairman. While serving on the Board, Mr. Pops’ outstanding equity awards will continue to vest in accordance with their terms based on his continued service relationship with the Company, and Mr. Pops will participate in the Company’s non-employee director cash compensation program. Upon the expiration of Mr. Pops’ service on the Board, (i) his outstanding time-based stock options that were scheduled to vest during the 21-month period following his service on the Board (the “Post-Service Vesting Period”) will vest, (ii) his performance-based stock options will remain outstanding during the Post-Service Vesting Period and will vest, if at all, based on actual performance (but will expire no later than the expiration date set forth in such stock options) and (iii) his 2025 performance-based restricted stock unit awards that were scheduled to vest during the Post-Service Vesting Period will remain outstanding and will vest, if at all, based on actual performance during the applicable performance period. In addition, upon the expiration of Mr. Pops’ service on the Board, the post-termination exercise periods of Mr. Pops’ outstanding stock options will be extended to the earlier of (i) the end of the Post-Service Vesting Period and (ii) the original expiration date of the applicable stock option. In the event of a change in control or sale event with respect to the Company following Mr. Pops’ service on the Board and prior to the end of

    2


     

    the Post-Service Vesting Period, his outstanding equity awards will become fully vested immediately prior to the closing of such transaction, with any performance-based vesting conditions determined in accordance with the terms of the applicable awards. Mr. Pops will also be reimbursed up to $60,000 in legal fees incurred in connection with the leadership transition.

     

    Item 7.01 Regulation FD Disclosure.

    On February 25, 2026, the Company issued a press release announcing Mr. Pops’ retirement as Chief Executive Officer of the Company and Mr. Jackson’s appointment as the incoming Chief Executive Officer of the Company, following Mr. Pops’ retirement. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference into this Item 7.01.

    The information in this Item 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

     

     

     

    99.1

     

    Press release issued by Alkermes plc dated February 25, 2026.

    104

     

    Cover page interactive data file (embedded within the Inline XBRL document).

     

    3


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    ALKERMES PLC

     

     

    Date: February 25, 2026

    By:

     

    /s/ David J. Gaffin

     

     

     

    David J. Gaffin

     

     

     

    Secretary

     

    4


    Get the next $ALKS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    2/24/2026$45.00Outperform
    Wolfe Research
    11/11/2025$50.00Buy
    Truist
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    9/3/2025$44.00Overweight
    Wells Fargo
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ALKS
    SEC Filings

    View All

    SEC Form 10-K filed by Alkermes plc

    10-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 9:31:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 9:31:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 7:05:28 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

    Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988

    2/25/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces CEO Succession Plan

    — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors — Alkermes plc (NASDAQ:ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board of Directors (the Board) appointed Blair Jackson, Alkermes' current Executive Vice President, Chief Operating Officer, as the company's next CEO, effective Aug. 1,

    2/25/26 6:55:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

    Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeli

    2/24/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Finance (Interim PAO) Parisi Samuel Joseph converted options into 5,025 units of Ordinary Shares and covered exercise/tax liability with 1,685 units of Ordinary Shares, increasing direct ownership by 43% to 11,057 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/20/26 4:25:51 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Commercial Officer Nichols Christian Todd converted options into 12,400 units of Ordinary Shares and covered exercise/tax liability with 4,146 units of Ordinary Shares, increasing direct ownership by 8% to 109,200 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/20/26 4:24:35 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Operating Officer Jackson Blair Curtis converted options into 18,197 units of Ordinary Shares and covered exercise/tax liability with 7,926 units of Ordinary Shares, increasing direct ownership by 5% to 231,823 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/20/26 4:23:16 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Alkermes Plc with a new price target

    Wolfe Research initiated coverage of Alkermes Plc with a rating of Outperform and set a new price target of $45.00

    2/24/26 7:45:07 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Alkermes Plc with a new price target

    Truist initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $50.00

    11/11/25 8:03:02 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Plc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00

    9/26/25 7:58:20 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

    Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988

    2/25/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visit

    2/11/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional ca

    11/19/25 6:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes plc Announces CEO Succession Plan

    — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors — Alkermes plc (NASDAQ:ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board of Directors (the Board) appointed Blair Jackson, Alkermes' current Executive Vice President, Chief Operating Officer, as the company's next CEO, effective Aug. 1,

    2/25/26 6:55:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care